$Cassava Sciences (SAVA.US)$ Bullish New Article: The curren...
$Cassava Sciences (SAVA.US)$ Bullish New Article: The current treatment scenario for Dementia Associated With Alzheimer's Disease is limited, and there is a need for more effective treatments that can address the underlying mechanisms of the disease. The report highlights the unmet needs in this area, including the need for novel approaches that can overcome the limitations of existing therapies. Emerging Drug: Simufilam: Cassava Sciences
Simufilam (formerly known as PTI-125) is an investigational drug being developed by Cassava Sciences. It targets an altered form of filamin A (FLNA), a protein implicated in the disease's pathology. Unlike traditional Alzheimer's treatments that focus on clearing amyloid plaques, simufilam works by stabilizing FLNA, thereby potentially reducing neuroinflammation and cognitive decline associated with the disease. Currently, the drug is in the Phase III stage of development to treat Dementia Associated With Alzheimer's Disease. Top Line Data Out Soon in less than 3 weeks.
Simufilam (formerly known as PTI-125) is an investigational drug being developed by Cassava Sciences. It targets an altered form of filamin A (FLNA), a protein implicated in the disease's pathology. Unlike traditional Alzheimer's treatments that focus on clearing amyloid plaques, simufilam works by stabilizing FLNA, thereby potentially reducing neuroinflammation and cognitive decline associated with the disease. Currently, the drug is in the Phase III stage of development to treat Dementia Associated With Alzheimer's Disease. Top Line Data Out Soon in less than 3 weeks.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Night Pig : Jayflash, I love all the updates! keep em coming. just loaded up more shares with Fridays dip!
JAYYFLASH OP Night Pig :
Coach Donnie : Let’s GOOO